No Prescription |
 |
 | ||
|
OLMECIP Benicar |
|
| ||
No Prescription » Prescription Drugs 12 » OLMECIP Benicar Olmesartan is used for: Treating high blood pressure alone or with other medicines. Olmesartan controls high blood pressure. It works by blocking the effect of a hormone called angiotensin II. Unopposed this substance prompts the blood vessels to contract an action that tends to raise blood pressure. Olmesartan relaxes and expands the blood vessels allowing pressure to drop. Olmesartan may be prescribed alone or with other blood pressure medications such as diuretics that help the body get rid of excess water. Olmesartan HCT provides just such a combination. It contains Olmesartan plus hydrochlorothiazide a common diuretic that increases the output of urine. This removes excess fluid from the body and helps lower blood pressure.Olmesartan is in a group of drugs called angiotensin II receptor antagonists. Olmesartan keeps blood vessels from narrowing which lowers blood pressure and improves blood flow. Buy OLMECIP Benicar and other Prescription Drugs 12 products online at Medstore. Buy Online at Medstore - Click Here!
About OLMECIP Benicar: Product Type: Prescription Drugs 12 OLMECIP ( Benicar Generic Olmesartan ) OLMECIP (Benicar Generic Olmesartan) Benicar Generic Olmesartan 20mg Benicar Generic Olmesartan OLMECIP
View more Prescription Drugs 12 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
